Next-Generation Biomanufacturing Market Size to Reach USD 54.85 Billion in 2032
The Next-Generation Biomanufacturing Market size was USD 25.10 Billion in 2024 and is expected to register a revenue CAGR of 10.2% during the forecast period
28 January, 2025 – Increasing investment in research and development (R&D) is a key factor driving market revenue growth. On April 2024, the Canadian government has invested USD 2.2 billion in 38 initiatives to improve biomanufacturing capacity, vaccine production, and medicinal discovery. Funding provided by Canada’s Advanced Manufacturing Cluster, the National Research Council, and the Strategic research Fund strengthened domestic pandemic response capabilities and life sciences research. The private sector has responded positively to prioritizing the expansion of local production capabilities for various, adaptable vaccination platforms, as well as permitting rapid scale-up during pandemics.
However, the revenue growth of Next-Generation biomanufacturing market is hampered by lack of skilled personnel. As the biotechnology business grows, there is a greater demand for skilled staff, which most companies cannot provide. One of the most difficult areas is providing technical support in upstream and downstream manufacturing. According to research, the biomanufacturing market has a skill gap of approximately 35%. It shows a shortage of skilled upstream and downstream process development personnel, as well as process engineers.
Key Highlights:
- Continuous upstream biomanufacturing segment is expected to register the highest growth rate over the forecast period. Upstream continuous processing, also known as perfusion processing, for biopharmaceutical production is developing as a viable manufacturing strategy. There have been several research articles in prior years on the development of recombinant therapeutic proteins, viral vectors, vaccinations, and cell therapy products. Perfusion applications are not restricted to the production process; they also cover various upstream areas where high cell density processes are required, such as cell bank preparation, N-1 seed bioreactor, and combination with intensified fed-batch production processes.
- Monoclonal antibodies segment is expected to account for the largest revenue share over the forecast period. MsAbs have many benefits over ordinary antibodies, including the capacity to be designed into powerful molecules that target several proteins while maintaining strong biochemical properties and unique capabilities. On November 2024, Vitrian, the leading end-to-end provider of investment capital and capacity building services for biomanufacturing, announced that it has closed a USD 50 million investment, with the option to increase to USD 65 million, in AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio, as part of a larger commitment to supporting biomanufacturing in Central Ohio. AmplifyBio is a leading advanced therapeutic CRO and CDMO that provides a comprehensive spectrum of medication development and manufacturing services.
- North America accounted for the largest revenue share in the Next-Generation biomanufacturing market in 2024 driven by increase in prevalence of chronic disorders and rising demand for advanced biomanufacturing processes. On June 2022, National Resilience, Inc., a technology-focused biomanufacturing firm dedicated to increasing access to complicated medications, announced that it has raised USD 625 million in a Series D funding, in addition to a previously revealed USD 600 million Series C. The funds will be used to expand the company’s infrastructure network through strategic collaborations, acquisitions, organic growth, and international expansion, as well as to develop innovative biomanufacturing technologies to ensure that today’s and tomorrow’s medicines can be manufactured quickly, safely, and in large quantities.
- Some major companies in the market report include Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffman La Roche, Danaher Corporation, Eppendorf AG, Sartorius AG, PBS Biotech, Inc, ZETA GmbH, GEA Group Aktiengesellschaft, Applikon Biotechnology, Esco Micro Pte Ltd, Pierre Guerin, Esco Group of Companies, and Shanghai Bailun Biotechnology Co. Ltd.
- On February 2024, National Resilience, Inc., a technology-focused biomanufacturing firm dedicated to increasing access to complicated medicines, and Taiwan Bio-Manufacturing Corporation (TBMC) have launched a ground-breaking joint venture that intends to alter the biomanufacturing industry. This collaboration addresses the growing demand for technology-enabled, comprehensive solutions for complex drugs. This joint venture focuses on creating cutting-edge manufacturing solutions for sophisticated treatment modalities such as biologics, vaccines, nucleic acids, cell therapy, and gene therapy.
Unlock the key to transforming your business strategy with our Next-Generation Biomanufacturing insights –
Navistrat Analytics has segmented Next-Generation biomanufacturing market based on workflow type, application, end-use, and region:
- Workflow Type Outlook (Revenue, USD Billion; 2022-2032)
- Single-Use Upstream Biomanufacturing Workflow
- Continuous Upstream Biomanufacturing
- Downstream Biomanufacturing Workflow
- Application Outlook (Revenue, USD Billion; 2022-2032)
- Vaccines
- Hormones
- Recombinant Proteins
- Monoclonal Antibodies
- Others
- End-Use Outlook (Revenue, USD Billion; 2022-2032)
- Biopharmaceutical companies
- Contract Research Organizations (CROs)
- Academic And Research Institutions
- Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America